Purpose: To develop a simple model of therapeutic and stray absorbed dose for a variety of treatment machines and techniques without relying on proprietary machine-specific parameters. Methods: Dosimetry measurements conducted in this study and from the literature were used to develop an analytical model of absorbed dose from a variety of treatment machines and techniques in the 6 to 25 MV interval. A modified one-dimensional gamma-index analysis was performed to evaluate dosimetric accuracy of the model on an independent dataset consisting of measured dose profiles from seven treatment units spanning four manufacturers. Results: The average difference between the calculated and measured absorbed dose values was 9.9% for those datasets on which the model was trained. Additionally, these results indicate that the model can provide accurate calculations of both therapeutic and stray radiation dose from a wide variety of radiotherapy units and techniques. Conclusions: We have developed a simple analytical model of absorbed dose from external beam radiotherapy treatments in the 6 to 25 MV beam energy range. The model has been tested on measured data from multiple treatment machines and techniques, and is broadly applicable to contemporary external beam radiation therapy.
INTRODUCTION
The goal of modern external beam radiotherapy is to deliver a highly targeted radiation dose to a diseased anatomic location or region while sparing the rest of the body. However, in practice, the whole body is unavoidably exposed to unwanted stray radiation. Healthy tissue in the margin of the treatment field will receive absorbed doses on the order of the prescribed dose. Tissues outside the treatment field receive stray dose from scattered and leakage radiation that is one to four orders of magnitude smaller. 1 Historically, clinical practices focused almost exclusively on in-field exposures because of their prime importance to curing primary cancers. In recent years, 5-year survival rates have surpassed 69% for all cancers 2 and 80% for childhood cancers, 3 but a myriad of radiation epidemiology studies have revealed the high prevalence of radiation-induced late effects including cardiac toxicity and radiogenic second cancers. 4, 5 Most radiogenic second cancers occur outside the therapeutic radiation field. [6] [7] [8] [9] [10] For these reasons, there is increasing interest in knowing the small stray radiation exposures to the whole body.
Many researchers have reported algorithms to model absorbed dose from external beam photon radiation therapy. [11] [12] [13] [14] In general, these algorithms accurately predict exposures inside and immediately outside the high-dose treatment field. However, none of these algorithms have fully addressed the stray dose far from the treatment field. Stovall et al. described three main sources of stray radiation from external beam radiation therapy delivered with electron linear accelerators. 15 Radiation scattered from the treatment head, known as head scatter, is primarily important within about 10 cm from the field edge. Patient scatter is an important source up to around 30 cm from the field edge. Finally, leakage radiation emanates from the treatment enclosure and predominates the stray radiation dose beyond about 30 cm. Monte Carlo simulations have been a useful research tool for modeling stray dose, [16] [17] [18] but these methods have not found use in clinical settings due to their complexity and long computational times. The feasibility of analytical models to predict stray dose from radiation therapy has been supported by several works, 7, [19] [20] [21] [22] [23] [24] [25] but few attempts have been made at developing models accurate for both in-field and out-of-field doses. Jagetic and Newhauser reported on one such model that accurately predicts absorbed dose from therapeutic, scatter, and leakage radiation. 26 This model was evaluated only at 6 MV photon-beam energy, only for conformal radiation therapy (CRT), and only for one type of electron linear accelerator (Elekta, SL25, Stockholm). The study left open important questions. First, is this approach extensible to other treatment techniques, e.g., intensity modulated radiation therapy (IMRT)? Secondly, is it adaptable to treatment units from other manufacturers? Third, can it be done without proprietary data?
The objective of this study was to determine whether a physics-based analytical modeling approach is applicable to a variety of treatment techniques and treatment units. More specifically, we characterized the dosimetric accuracy that can be achieved without the use of proprietary and machinespecific parameters to configure the model. In order to accomplish this, we developed a new analytical model that can be configured with measured dose profiles that are similar to those used for configuring commercial treatment planning systems. The model was tested using measured data from a variety of treatment machines and techniques in the 6-25 MV interval of photon beam energy.
METHODS AND MATERIALS

2.A. Analytical model
The analytical model consists of four terms: one to model the therapeutic radiation dose and three to model sources of stray dose, or
where D T is the total dose from all sources, D P is the primary dose term that models the therapeutic dose, D HS is the first stray dose term that models dose from head scattered radiation, D PS is the second stray dose term that models dose from patient scattered radiation, and D L is the third stray dose term that models leakage radiation. Consequently, simplicity and ease of use were of prime importance to the model's design. In particular, we designed it for ease and simplicity of configuration, e.g., by using nonproprietary data that can be quickly measured in most clinics. The model proposed in this work shares the major underlying physics and mathematical form as that of Jagetic and Newhauser, but it was radically simplified here to streamline the configuration process and to eliminate the use of proprietary data. As will become readily apparent later, these two features were of prime importance in configuring the model for multiple treatment techniques and machines. Table I compares the two models and detailed descriptions of the terms from this work follow below.
The primary absorbed dose, D P , for square and rectangular fields is given by D P ¼ A P Â Cðx; zÞ Â Cðy; zÞ Â TF P;w ðx; y; z; EÞ (2) where A P governs the amplitude of the primary dose on the central axis, C(x,z) and C(y,z) govern the width and lateral penumbrae of the beam in the x and y directions, x and y are the lateral distances from central-axis in the plane of calculation for the in-and cross-plane directions, and TF P,w (x,y,z,E) is the transmission factor of the primary portion of the beam of nominal energy E at a point (x,y,z) in a phantom. The C functions in (2) model the shape of the primary dose via the simple but realistic approach of using cumulative normal distributions, as in
where r P (z) is the width parameter for the cumulative normal functions used to define the penumbra, and x P ðzÞ and y P ðzÞ are the centroids of the cumulative normals projected to depth z. These parameters are described in detail below. The parameters r P (z), xðzÞ, and yðzÞ are scaled with depth according to r P ðzÞ ¼ r P;0 Â F P ðzÞ;
xðzÞ ¼ x P;0 Â F P ðzÞ;
yðzÞ ¼ y P;0 Â F P ðzÞ;
where r P,0 is the width parameter in the isocentric plane, x P;0 and y P;0 are the lateral field edge locations in the isocentric plane. F P (z) is the scaling factor defined as
where SSD is the source-to-surface distance, d iso is the depth at isocenter, and a P is an empirical correction factor to the rate at which r P (z), x P ðzÞ, and x P ðzÞ change with depth. The transmission factor in water at the calculation point is given by TF P;w ðx; y; z; EÞ ¼ exp Àl P;eff Â dðx; y; zÞ
where the path length through water to point (x,y,z) is
The effective linear photon attenuation coefficient is
where l P,eff (E) is the effective linear attenuation coefficient in water for the primary portion of a beam of nominal energy E, and lj w; E is the linear attenuation coefficient in water for photons of energy E, where E is the average energy of the photon beam approximated as one third the value of the nominal energy following Jagetic and Newhauser. 26 The parameters b l,P and m l,P are the 0 th and 1 st order coefficients, respectively, of an empirical correction factor to the effective linear attenuation coefficient that is parameterized with energy. This factor is needed because lj w; E will not equal the true energy weighted mean of the linear attenuation coefficient, l(E), across the full energy spectrum of the beam. The values of the parameters b l,P and m l,P are determined along with the other fitting parameters via the model training procedure described in Section 3. The values of lj w; E for the energies considered in this study were found from the National Institute of Standards and Technology (NIST) XCOM photon cross-sections database. 27 The stray dose is the sum of three terms. The head scatter dose term is the narrowest laterally and is given by 
where A HS (E) is the energy-dependent scaling factor given by
b HS and c HS are the 1 st and 0 th order coefficients, respectively, that parameterize the factor with photon beam energy. The depth-dependent width parameter, r HS (z), is given by r HS ðzÞ ¼ r HS;0 Â F HS ðzÞ;
where r HS,0 , is the head scatter width parameter in the isocentric plane, F HS (z) is defined similarly to (7) with empirical adjustment factor a HS , and TF HS,w (x, y, z, E) is the 
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where A PS (E) is the energy-dependent scaling factor
b PS and c PS are the 1 st and 0 th order coefficients, respectively, that parameterize the scaling factor with photon beam energy, and r PS (z) is a depth-dependent width parameter that scales with depth according to r PS ðzÞ ¼ r PS;0 Â F HS ðzÞ;
where r PS,0 is the head scatter width parameter in the isocentric plane and F PS (z) is defined similarly to (6) with empirical adjustment factor a PS . The transmission factor for radiation from patient scatter in a water phantom is given by
The functional form of the leakage dose term is illustrated in Fig. 1 and is defined as 
where
and F / accounts for increased leakage present in treatments with large amount of photon fluence modulation. The depthdependent width parameter from (18) is
where F L (z) is defined similarly to (7) with a corresponding empirical adjustment factor a L . The factor [1 À C(x,z)9C(y, z)] suppresses the leakage term inside the treatment field, and PC(r,z,E) models attenuation in the primary collimator. This primary collimator function is given by
where r ¼ ffiffiffiffiffiffiffiffiffiffiffiffiffiffi
r PC (z) is the width parameter of primary collimator penumbra given by
and rðzÞ is the lateral location of the primary collimator projected to depth z as in
2.B. Measurements
There are three distinct sets of measured dosimetric data considered in this manuscript summarized in Table II . The first set was obtained in this study under the auspices of the European Radiation Dosimetry (EURADOS) Working Group 9 (WG9), a multinational collaboration of institutions and researchers dedicated to research and development in In the in-field region, the leakage dose is defined to be zero. In the intermediate region, leakage is attenuated by the secondary collimator. Far out of field, there is additional attenuation from the primary collimator. the field of radiation dosimetry in medicine. 1 These experiments were specifically designed to yield dosimetric data that was needed to understand and model the physics of stray radiation exposure. The measurement methods and a limited number of preliminary results were previously reported by Bordy et al. 28 The EURADOS dataset consists of measurements made with multiple types thermoluminescent dosimeters (TLDs), radiophotoluminescent dosimeters (RPLs), and optically stimulated luminescent dosimeters (OSLDs) of doses delivered by a Saturne 43 linac (GE Medical Systems, USA). The calibration procedure for the various types of dosimeters is described by Kne zevi c et al. 29 Doses were measured at various locations inside a 30 9 30 9 60 cm 3 water phantom. This dataset includes dose profiles at 10, 15, 20, and 25 cm depths in water with a source-to-surface distance (SSD) of 90 cm, a field size of 10 9 10 cm 2 , and beam energies of 6, 12, and 20 MV. The irradiations each delivered a reference dose of 2 Gy to the isocenter located at 10 cm depth. The measurements from this dataset are being prepared for distribution in the form of electronic files containing complete tables of all numerical data and will be available for download from the EURA-DOS website (http://www.eurados.org).
The second dataset used in this work comprises measurements performed at the Klinikum Goethe Universit€ at (KGU) in Frankfurt, Germany. The KGU dataset measurements were made with a diamond detector model (60003 PTW, Freiburg) of doses delivered by an SL25 linac (Elekta, Stockholm) for various field sizes, depths, and beam energies. For this work, we consider 10 9 10 cm 2 fields at depths of 1.5 and 3.5 cm in water and 100 cm SSD for beam energies of 6, 18, and 25 MV. These measurements were previously published in Kaderka et al. 30 The third dataset used in this work comprises doses measured in an anthropomorphic phantom (Alderson-Rando, RSD Radiology Support Devices, Long Beach, CA, USA) for a variety of widely used treatment machines and treatment techniques. These measurements were previously published in Halg et al. 10 Prostate treatment plans were created for nine treatment techniques from four manufacturers, including Accuray (Sunnyvale, CA, USA), Elekta (Stockholm, Sweden), Varian Medical Systems (Palo Alto, CA, USA), and Siemens (Berlin, Germany). All beams in this dataset had a nominal energy of 6 MV. The dose measurements were performed using TLDs placed inside the anthropomorphic phantom. The dose along the medial patient axis was determined using 34 TLDs spaced at 2.5 cm intervals from the target (in prostate) to the head.
2.C. Model training
In this work, the analytical model was trained separately using the EURADOS and KGU datasets. Training was accomplished by simultaneously fitting the parameters listed in Table V to measured dose values at all locations and at all beam energies. We used a gradient search algorithm to vary the free parameters and minimize the sum of the local relative differences, DD Total , between the predicted and measured values. The sum of total relative differences was defined according to
where n is the number of data points. In order to characterize the goodness of fit, we calculated
where DD is the average local relative difference, and
where DD max is the maximum of the local relative differences.
2.D. Model validation
The model, as configured and trained on both the KGU and EURADOS datasets, was validated by comparison with independent data, namely, the measured dose profiles in an anthropomorphic phantom for several treatment machines and techniques. Variations in depth due to the irregular surface contour of the phantom were modeled implicitly since it has been demonstrated that these variations are modest. 24 We compared the model as trained on two independent training datasets in order to test the sensitivity of the agreement to the choice of training data.
The quality assurance technique known as gamma analysis, first described by Low et al, 32 characterizes the agreement between measured and calculated dose distributions on a point by point basis by combining dose difference and distance to agreement criteria. In most radiotherapy clinics, the dose difference criterion is selected at 3% of the maximum dose, and the distance to agreement criterion at 3 mm. These values are commonly known as the Van Dyk criteria. 33 However, this choice is not suitable for application far outside of the treatment field since dose in this region is well under 3% of the maximum dose, rendering the test insensitive to important dose errors in the out-of-field region. To overcome this limitation, we extended the gamma index analysis method in order to provide sufficient sensitivity and dynamic range to characterize dosimetric agreement in both the in-field and out-of-field regions.
The gamma indices at all positions in therapeutic and outof-field dose regions were calculated according to
where x m and x c are the locations of measured and calculated dose values, respectively. r(x m , x c ) is the difference in position between measured and calculated dose values, Dd T and Dd OOF are the distance to agreement criteria in the therapeutic and out-of-field regions, respectively, d R (x m , x c ) represents the relative dose difference between measured and calculated dose values, DD R is the relative dose difference criterion, d A (x m , x c ) represents the absolute dose difference between measured and calculated dose values, and DD A is the absolute dose difference criterion. The therapeutic dose region was delineated from the out-of-field dose region at the 1% relative dose level based on previously published findings. 26, [34] [35] [36] This allows for a significantly more severe dosimetric test out-of-field than conventional methods. Gamma index analysis was performed separately comparing the analytical model calculations on each of the two training datasets to the anthropomorphic phantom dataset for the Varian Clinac 21 iX CRT. Gamma index pass rates were selected at 100%, 95%, 90%, and 67%. The corresponding gamma index criteria were iteratively decreased until the analysis yielded the selected pass rate. Table III shows the average and local relative differences for the model compared with the KGU dataset including the 6 MV beam at a depth of 1.5 cm and the 18 and 25 MV beams each at a depth of 3.5 cm. The average local relative difference, defined in (26), was 9.9%. The maximum local relative difference, defined in (27) , was 33%. Table IV lists the average and maximum local relative differences for all energies and depths included in this dataset. The average difference for all locations and energies considered was 9.9% and the maximum difference was 41%.
RESULTS
3.A. Model training
The model parameter values resulting from fitting the model to the KGU and EURADOS datasets of measurements in water are listed in Table V differences between the parameters as fit on these datasets are also listed. The primary dose parameters resulting from fitting the model to each of the two datasets are similar with no parameter differing by more than 33.5%. However, there are considerable differences between the parameters for the out-of-field dose components, thus highlighting the ability of the model to adapt to out-of-field dose profiles of different machines.
3.B. Validation with anthropomorphic phantom measurements
Doses measured in an anthropomorphic phantom for all nine treatment machines considered are shown in Fig. 6 . Also shown on this plot are the calculated doses from the analytical model as trained on both the KGU and EURADOS datasets from the previous section. The gamma index criteria required to achieve the selected passing rates are listed in Table VI .
The large differences in leakage radiation seen in the measured profiles in Fig. 6 are due to differences in the fluence modulation used for the different techniques, as well as variations in collimators and head shielding in various machines. For example, the increased leakage from the CyberKnife unit was likely due to reduced head shielding in order to facilitate the mounting of the linac on a robotic arm. On the other hand, the increased leakage from the wedged field technique was due to the greater beam-on time required to produce wedged fields. Dose profiles from special techniques such as these should not be expected to closely match the dose profiles of more typical treatment techniques, e.g., IMRT. By fitting the model parameters for each curve individually, it is possible to faithfully reproduce each of the measured dose profiles in a descriptive capacity (not shown), but additional development is necessary to extend the model to include explicit modeling of fluence modulation for predictive purposes. 
DISCUSSION
This work strongly suggests that there is potential for improving the completeness and accuracy of dose distribution calculations in routine clinical applications. The model is not intended to replace current methods of treatment planning, but could be used in conjunction with current methods to provide a level of accuracy for the dose far outside the treatment field that is not available from currently available commercial treatment planning systems. With further study, this model could be implemented for use in hand calculations of fetal dose in the case of a pregnant radiation therapy patient or the dose to implants such pacemakers that may be damaged by radiation. Additionally, the ability to calculate therapeutic and stray radiation with a single model should be useful for studies in radiation epidemiology or as an educational tool for demonstrating the shape and relative magnitudes of the dose distributions from various treatment machines and techniques. Importantly, this may all be possible with a single analytical model that users may implement with measured data that is likely to already exist for their clinic.
The results of this study are coherent with previous works related to analytical models of total dose from external beam radiation therapy. In particular, the results achieved in this work agree well with those of a more complex model previously reported by Jagetic and Newhauser. 26 The model offers simplicity, easy portability to various treatment machines and techniques, and increased speed compared with the more detailed model of Jagetic and Newhauser.
Major strengths of this study include the large number of treatment machines and techniques considered. Although previous works have been limited to single treatment techniques, this work considers nine techniques delivered with seven treatment machines from four manufacturers. This is made possible by the simplicity of the reported model. Additionally, in demonstrating the accuracies that are achievable with such a simple model, this work informs about the tradeoff between accuracy and complexity for analytical dose models.
Limitations of this work include the limited amount of measured data taken for each treatment technique. Additionally, only the descriptive capabilities of the model have been examined in this work, and the model's ability to predict doses for treatments with different setup conditions has not been tested. This is not a serious limitation because a lookup table approach could be used to apply this model to many different setup conditions with only a few measurements required. Another limitation of the model, in its current form, is the lack of photoneutrons at beam energies greater than 10 MV. However, this is not a serious limitation because most external beam photon treatments are delivered with 6 MV beams. This is especially true of IMRT. Additionally, for beam energies up to 18 MV, the component of equivalent dose due to photoneutrons is a small fraction of that due to leakage photons. 30 Also, the model can be extended to include photoneutrons in future studies. Other future work should include testing the model for dosimetric accuracy under different treatment conditions, such as field size.
Additionally, implementing the model into a treatment planning system would allow for further testing of the practicality of using analytical models of stray dose in clinical settings. Our research group has recently performed similar work by implementing an analytical model of neutron dose from passively scattered proton therapy into a research treatment planning system. 37 
CONCLUSION
In this work, we developed a new, broadly applicable analytical model of the total dose from external beam radiation therapy. The model provides very good accuracy, on average better than 10%, for both therapeutic and stray dose for a wide variety of treatment machines and techniques when compared with measured data. Importantly, the model developed here may be configured using non-proprietary configuration parameters and dosimetric data that is readily measurable in most clinics.
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